Director, Allied Health
School of Allied Health Science and Practice
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Professor Rachel Gibson is the inaugural Professor and Director of Allied Health at the University of Adelaide. In addition, she is Co-Head of the Cancer Treatment Toxicities Group at the Adelaide Medical School, along with Professor Joanne Bowen and Dr Janet Coller. Prior to this role, Rachel was the inaugural Professor and Dean: Academic in the Division of Health Sciences, University of South Australia.
- My Research
- Grants and Funding
- Professional Activities
Rachel's main research interest is supportive care in cancer. Rachel works with a team of researchers from the fields of pathology, molecular biology, microbiology, and immunology, among others, in the study of toxic effects of chemotherapy on the gut microbiome of cancer patients and the development of clinically diagnosed diarrhea, a manifestation of intestinal mucositis. She is a prolific researcher in this field, and has authored or co-authored over 120 journal articles (including 15 in Supportive Care in Cancer), six book chapters, and 75 abstracts presented at the MASCC Annual Meetings. She has also been a leader in MASCC Study Group initiatives (Mucositis and Oral Care) in developing clinical practice guidelines for the management of mucositis secondary to cancer therapy, including gastrointestinal mucositis. These efforts demonstrate her dedication to promoting supportive care knowledge and practice on a global scale. Rachel is recognized as a skilled communicator among peers, students, business collaborators, and partners, and has been an enthusiastic advocate for Supportive Care in Cancer.
Date Position Institution name 2019 - ongoing Inaugural Professor and Director, Allied Health University of Adelaide 2016 - 2019 Professor (Level E) University of South Australia 2016 - ongoing Head of Group University of Adelaide 2014 - 2015 Associate Professor (Level D) University of Adelaide 2010 - 2013 Senior Lecturer (Level C) University of Adelaide 2007 - 2009 Lecturer (Level B) University of Adelaide 2004 - 2009 Research Fellow Royal Adelaide Hospital
Awards and Achievements
Date Type Title Institution Name Country Amount 2020 Award University of Adelaide Exceptional Leadership for an Academic University of Adelaide Australia 2019 Award Distinguished Service Award Recipient Multinational Association for Supportive Care in Cancer United States 2013 Scholarship South Australian Professional Development Scholarship Department for Science and Training, South Australian Government Australia 2013 Award Dean's Excellence in Teaching University of Adelaide, Faculty of Health Sciences Australia 2011 Recognition Best of the Best- Translational Research-Finalist Clinical Oncology Society of Australia Annual Scientific Meeting Australia 2010 Recognition South Australian Marie Claire Young Business Woman of the Year-Finalist Telstra Business Women's Awards Australia 2004 Fellowship Post-Doctoral Research Fellowship Cancer Council of South Australia Australia
Date Institution name Country Title 2004 University of Adelaide Australia Doctor of Philosophy University of Abuja Australia Bachelor of Health Sciences (Honours)
Year Citation 2019 Coller, J. K., Korver, S. K., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R. M., . . . Bowen, J. M. (2019). Predictors of severe gastrointestinal toxicity risk in patients treated with 5-fluorouracil-based chemotherapy: A validation study. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. 2017 Korver, S. K., Ball, I. A., Gibson, R. J., Logan, R. M., Karapetis, C. S., Keefe, D. M., . . . Coller, J. K. (2017). The Effect of Immune Genetic Variants on Chemotherapy-Induced Gastrointestinal Toxicity (CIGT) Risk in Patients Receiving 5-Fluorouracil. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. 2017 Korver, S. K., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R. M., Richards, A., . . . Coller, J. K. (2017). Interleukin-1 Beta (IL1B) Genetic Variability is Predictive of Chemotherapy-Induced Gastrointestinal Toxicity (CIGT) Risk in Patients Receiving 5-Fluorouracil. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. 2017 Bautista, M. J., Ahmedzai, S. H., Bouzid, K., Gibson, R., Gumara, Y., Hassan, A. A. I., . . . Wang, J. J. (2017). A framework for education and advocacy for optimal cancer pain management in resource-limited settings. Poster session presented at the meeting of Annals of Oncology. Singapore, SINGAPORE: OXFORD UNIV PRESS.
2015 Stansborough, R. L., Bateman, E., Al-Dasooqi, N., Keefe, D., & Gibson, R. (2015). Microvascular injury and associated mediator changes occur during acute radiotherapy-induced gut toxicity. Poster session presented at the meeting of Supportive Care in Cancer. Copenhagen, Denmark: Springer Verlag (Germany). 2009 Stringer, A. M., Gibson, R. J., Bowen, J. M., Logan, R. M., Al-Dasooqi, N., & Keefe, D. M. K. (2009). Chemotherapy-induced diarrhoea is associated with a modified microbiome in cancer patients. Poster session presented at the meeting of Abstracts of the Australia & New Zealand Medical & Surgical Gastrointestinal Week 2009, as published in Journal of Gastroenterology and Hepatology. Sydney, N.S.W.: Wiley-Blackwell.
2000 Gibson, R., Keefe, D., Clarke, J., Regester, G., Edwards, B., Thompson, F., . . . Cummins, A. (2000). Interleukin-11 (IL-11) reduces, but not completely ameliorates, intestinal mucositis following chemotherapy in the rat with breast cancer. Poster session presented at the meeting of Abstracts for Australian Gastroenterology Week 2000. Victoria, Australia: Blackwell Science Asia.
Recorded/Rendered Creative Works
Year Citation 2015 Authors: Ricci M, Karanicolas, Snelling C, Gibson R, Buisman-Pijlman. Title: Essential Human Biology: Cells and Tissues MOOC. Description: N/A. Extent: 5 weeks. 2015 Authors: Ricci M, Karanicolas, Snelling, Buisman-Pijlman, gibson R. Title: Essential Human Biology: Cells and Tissues YouTube Channel. Description: N/A. Extent: 50 videos.
Year Citation 2016 Wardill, H. (2016). Toll-like receptor 4-dependent barrier dysfunction and its impact on irinotecan-induced gut toxicity and pain. (PhD Thesis). 2015 Mohd Rasoul, A. (2015). The expression of matrix metalloproteinases and tissue inhibitor for metalloproteinases in the Keratocystic Odontogenic Tumour. (Master's Thesis). 2013 Al-Azri, A. S. (2013). The role of matrix metalloproteinases and their inhibitors in irinotecan-induced oral mucositis: an animal model. (PhD Thesis, The University of Adelaide).
|Date||Project/ No.||Investigators||Funding Body||Amount|
|2019-2020||Nutritional interventions for chemotherapy-induced gastrointestinal dysfunction in rats with cancer||Bowen JM, Gibson RJ||PanTheryx Pharmaceticals||$190,000.00|
|2016-2017||Mucositis therapy with AstraZeneca’s AZD1236||Gibson RJ, Bowen JM||Commercial Accelerator Scheme / Open Innovation Scheme||$80,000.00|
|2015-2019||Improved oral delivery of encapsulated biological agents by targeting epithelial M cells
||Prestidge C, Thierry B, Gibson RJ, Khartri A, Barbe C||ARC Linkage Grant||$396,547|
|2015-2018||A combined pre-clinical and clinical investigation of the role of TLR4 in chemotherapy-induced gut toxicity||Gibson RJ, Bowen JM, Coller JK, Keefe DM||Ray and Shirl Norman Cancer Research Trust||$450,000|
|2015-2016||Translating concept into practice: enabling first-year health sciences teachers to blueprint effective flipped learning approaches||Karanicolas S, Ricci M Snelling C, Chittleborough C, Chapman J, Douglas T, Williams A, Gamble N, Williams P, Peirce E, Gibson R, Winning T, Milazzo A, Peterson R, Willison J,||Office of Learning and Teaching Australia||$225,000|
|2015||Abrogating inflammation and bone loss in a mouse model of inflammatory arthritis||Crotti TN, A Dharmapatni, Gibson RJ, Perilli E||Arthritis Australia||$25,000|
|2014-2015||Determining the underlying mechanisms of gastrointestinal toxicity induced by Oprozomib (invitro)||Gibson RJ||Onyx Pharmaceuticals/Amgen||$112,454|
|2014-2016||Determining the underlying mechanisms of gastrointestinal toxicity induced by Oprozomib (invivo)||Gibson RJ||Onyx Pharmaceuticals/Amgen||$235,742|
|2014-2015||Essential Human Biology: Cells and Tissues MOOC (Massive, Open, Online, Course)||Ricci M, Karanicolas S, Buismen-Piljman F, Gibson RJ||University of Adelaide/ AdelaideX||$50,000|
|2014||Chemotherapy-induced alimentary mucositis: do tight junction disruptions translate from the gut to the oral cavity||Wardill HR, Logan RM, Gibson RJ||Australian Dental Research Foundation||$5200|
|2013-2014||Novel non-surgical skin cancer therapy using non-themal atmospheric pressure plasma||Kim MK, Gibson R||ECMR Adelaide||$18,655|
|Flipping the classroom to enhance the first year student experience through the use of interactive learning technologies for student centric learningFlipping the classroom to enhance the first year student experience through the use of interactive learning technologies for student centric learningDVCR – University of Adelaide||Karanicolas S, Snelling C, Ricci M. Peirce E, Gibson R, Winning T, Milazzo A, Peterson R, Willison J||DVC Student Experience – University of Adelaide||$15,000|
|2012-2013||Automated Immunohistochemistry Machine and PT Link for research||Gibson RJ, Bowen JM, Leigh CM, Roberts C and Butler LM||DVCR – University of Adelaide||$68,500|
|2012||Are the matrix metalloproteinases and the tissue inhibitors of metalloproteinases upregulated in the oral mucosa following chemotherapy||Al-Azri, A, Gibson RJ, Keefe DMK, Logan RM||Australian Dental Research Foundation||$4000|
|2011-2012||Validation of a model of colon inflammation (colitis) using ex vivo human colonic mucosal explant tissue as a viable alternative to animal models of colitis||Smid S, Gibson RJ||Medical Advances without Animals||$28,122|
|2011-2012||South Australian Professional Development Scholarship||Gibson RJ||Department for Science and Technology (South Australian Government)||$15,000|
|2010-2011||Functional Expression of the Endocannabinoid System in Inflammatory Bowel
|Smid S, Gibson RJ, Cummins AG||Broad Medical Research Program||$US128,694|
|2010-2011||Matrix Metalloproteinases: Key regulators in the pathogenesis of chemotherapy-induced mucositis||Al-Dasooqi N, Gibson RJ, Bowen JM, Keefe, DMK||GlaxoSmithKline||$25,000|
|2009||Faecal microflora and circulating proinflammatory cytokines: key elements to chemotherapy-induced diarrhoea||Gibson RJ, Bowen JM, Stringer AM, Logan RM||Cancer Australia/Cure Cancer Australia||$75,000|
|2009||Intestinal Stem Cells||Cummins AG, Roberts-Thomson I, Hardingham J, Gibson RJ||Cancer Council South Australia||$101,000|
|2009||Faecal microflora and circulating proinflammatory cytokines: key elements to chemotherapy-induced diarrhoea||Gibson RJ||The University of Adelaide, Faculty of Health Sciences Seed Funding||$10,000|
|2009||Development of the Wistar Rat model for mucositis||Bowen JM and Gibson RJ||The University of Adelaide, ARI seed funding||$26,200|
|2006||Oral mucositis: clinical presentation, histological features and proinflammatory cytokine expression||Logan RM, Gibson RJ, Keefe DMK and Sonis ST||Australian Dental Research Foundation Inc||$3000|
|2006||Chemotherapy-induced diarrhoea: Characterisation of Mechanism||Keefe DMK, Gibson RJ, Bowen JM, Stringer AM and Logan RM||Cancer Council South Australia||$70,500|
|2005||Oral mucositis: relationship between transcription factor expression changes, cytokine expression, apoptosis and subsequent damage||Gibson RJ, Logan RM and Keefe DMK||RAH Research Fund||$19,610|
|2004-2005||CG53135-05 and chemotherapy-induced intestinal mucositis||Keefe DMK, and Gibson RJ||CuraGen Inc||$US 300,000|
Teaching and Training Innovations and Curricula Development
|2019-current||Led all curricula development for the launch of three new undergraduate programs at the University of Adelaide: Bachelor of Occupational Therapy (Hons); Bachelor of Physiotherapy (Hons); Bachelor of Speech Pathology (Hons)|
|2016-2019||Variety of curricula development as Dean: Academic; Division of Health Sciences; University of South Australia. This included Online Bachelor Degree programs; international offshore delivery programs and postgraduate programs|
|2015-2017||Office of Learning and Teaching Grant: Translating concept into practice: enabling teachers to blueprint flipped learning approaches in first-year health sciences.|
|2014-2015||MOOC (Mass Online Open Course): Essential Human Biology: Cells and Tissues; Academic Presenter|
|2013-2014||Flipped Classroom Approach: 1st Year Nursing, University of Adelaide|
|2009-2011||Year 1 MBBS Convenor, Bachelor of Medicine and Surgery, University of Adelaide|
|2010-2011||Course Development for Fundamentals of Biomedical Science A and B: 1st Year MBBS, University of Adelaide|
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2022 Principal Supervisor What impact could greenspace interventions have on people with chronic respiratory conditions? Master of Philosophy (Clinical Science) Master Full Time Mrs Amanda Maddern 2021 Principal Supervisor Advancing physiotherapy management of chronic pain by improving implementation of evidence-based practice. Doctor of Philosophy Doctorate Part Time Mr Cameron Dickson 2021 Principal Supervisor Tailoring Chronic Pain Assessment for Children with Cerebral Palsy Doctor of Philosophy Doctorate Part Time Mrs Meredith Smith 2021 Principal Supervisor Can a nature-based physiotherapy program increase diversity of gut microbiota and improve outcomes for adolescents with chronic abdominal pain? Master of Philosophy (Medical Science) Master Part Time Mrs Trish Serocki
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2017 - 2021 Co-Supervisor Exploration of the gut microbiome as a predictive factor for cancer treatment-induced gastrointestinal toxicity Doctor of Philosophy Doctorate Full Time Miss Kate Rebecca Secombe 2016 - 2020 Co-Supervisor Identifying potential genetic, phenotypic and epigenetic predictive markers in the Toll-like receptor/Interleukin-1 domain innate immune signalling pathway for severe gastrointestinal toxicity risk following 5-Fluorouracil-based therapy Doctor of Philosophy Doctorate Full Time Miss Samantha Kaitlyn Korver 2015 - 2018 Co-Supervisor Clinical and Microbiological Effects of Probiotics in Experimental Induced Periodontitis Doctor of Philosophy Doctorate Full Time Mrs Simona Gatej 2014 - 2017 Co-Supervisor Characterisation and Treatment of Pan-Human Epidermal Receptor Tyrosine Kinase Inhibitor-Induced Gastrointestinal Toxicity Doctor of Philosophy Doctorate Full Time Ysabella Van Sebille 2014 - 2018 Principal Supervisor Intestinal Microvascular Changes and Matrix Metalloproteinases in Radiotherapy-Induced Gastrointestinal Toxicity Doctor of Philosophy Doctorate Full Time Romany Laura Stansborough 2013 - 2016 Principal Supervisor Toll-Like Receptor 4-Dependent Barrier Dysfunction and its Impact on Irinotecan-Induced Gut Toxicity and Pain Doctor of Philosophy Doctorate Full Time Dr Hannah Rose Wardill 2012 - 2016 Co-Supervisor Does Transgenic Feed Cause Histopathological Changes in Rats? Doctor of Philosophy Doctorate Full Time Dr Irena Zdziarski 2010 - 2013 Co-Supervisor The Role of Matrix Metalloproteinases and their Inhibitors in Irinotecan-Induced Oral Mucositis: An Animal Model Doctor of Clinical Dentistry Doctorate Full Time APrf Abdul Rahman Al 'Azri 2008 - 2012 Principal Supervisor Chemotherapy-Induced Mucositis: The Role of Matrix Metalloproteinases and the Extracellular Matrix Doctor of Philosophy Doctorate Full Time Miss Noor Al-Dasooqi 2006 - 2009 Co-Supervisor Chemotherapy-Induced Mucositis: The Role of Gastrointestinal Microflora and Mucins in the Luminal Environment Doctor of Philosophy Doctorate Full Time Dr Andrea Marie Stringer
Date Role Board name Institution name Country 2021 - 2016 Board Member Multinational Association of Supportive Care in Cancer Board MASCC United States 2018 - 2020 Treasurer Multinational Association of Supportive Care in Cancer Multinational Association of Supportive Care in Cancer United States 2016 - 2021 Secretary Multinational Association of Supportive Care in Cancer MASCC United States 2014 - 2016 Board Member Multinational Association for Supportive Care in Cancer Multinational Association for Supportive Care in Cancer United States
Date Role Committee Institution Country 2021 - 2021 Board Member National Health and Medical Research Council Investigator Grant Panel National Health and Medical Research Council Australia 2020 - 2016 Chair Multinational Association for Supportive Care in Cancer Awards Committee Multinational Association for Supportive Care in Cancer United States 2020 - 2020 Member California Institute for Regenerative Medicine Discovery Stage Program California Institute for Regenerative Medicine United States 2020 - 2020 Member National Health and Medical Research Council Ideas Panel National Health and Medical Research Council Australia 2020 - 2020 Member National Health and Medical Research Council GACD Cancer Prevention Panel National Health and Medical Research Council Australia 2019 - 2020 Member National Health and Medical Research Council Investigtor Panel National Health and Medical Research Council Australia 2018 - 2020 Member California Institute for Regenerative Medicine Discovery Stage Program California Institute for Regenerative Medicine United States 2017 - 2017 Member California Institute for Regenerative Medicine Discovery Stage Program California Institute for Regenerative Medicine United States 2016 - ongoing Member Project Grants Panel 2C: Endocrinology, Diabetes, Gastroenterology, Musculoskeletal & Obesity NHMRC Australia 2016 - ongoing Advisory Board Member Therapeutic Goods Assessment and Advisory Services Panel Australia 2016 - ongoing Secretary MASCC Board of Directors Multinational Association for Supportive Care in Cancer 2016 - ongoing Chair MASCC Annual Scientific Meeting Multinational Association for Supportive Care in Cancer 2014 - 2015 Chair MASCC Awards Committee Multinational Association for Supportive Care in Cancer 2014 - 2015 Member MASCC Board of Directors Multinational Association for Supportive Care in Cancer 2014 - 2015 Member Onyx Pharmaceuticals Oprozomib GI Tolerability Advisory Board Onyx Pharmaceuticals United States 2014 - 2015 Member Project Grants Panel 3A: Endocrinology, Diabetes, Gastroenterology, Musculoskeletal & Obesity Australia 2008 - ongoing Member Clinical Oncological Society of Australia (COSA) Australia 2004 - ongoing Member Member of the Multinational Association of Supportive Care in Cancer (MASCC) 2004 - ongoing Member International Mucositis Study Group 2004 - ongoing Member International Oral Care Study Group 2003 - ongoing Member Australian Society for Medical Research (ASMR) Australia
Date Institution Department Organisation Type Country 2019 - 2020 PanTheryx Pharmaceuticals RSD Scientific research United States 2017 - 2020 Kaleido Biosciences RSD Scientific research United States
Date Role Editorial Board Name Institution Country 2016 - ongoing Editor Current Opinion in Supportive and Palliative Care Gastrointestinal Symptoms United Kingdom
Connect With Me